Pfizer's New Drug Velsipity Poised to Challenge AbbVie's Dominance in Inflammatory Bowel Disease Market
-
Pfizer's new ulcerative colitis drug Velsipity was approved by the FDA, putting it in competition with AbbVie's leading therapies.
-
Velsipity could also compete with AbbVie's Skyrizi and Rinvoq in treating Crohn's disease, alopecia areata, atopic dermatitis, and more.
-
Pfizer is seeking to expand indications for its alopecia drug Litfulo, which could also compete with AbbVie.
-
Velsipity will also compete with Bristol Myers Squibb's Zeposia in the ulcerative colitis market.
-
While the impact is uncertain, Velsipity's approval increases the likelihood of revenue headwinds for AbbVie as Pfizer tries to grab market share.